AstraZeneca Debate
Full Debate: Read Full DebateDepartment: Department for Science, Innovation & Technology
Bill Esterson
Main Page: Bill Esterson (Labour - Sefton Central)Department Debates - View all Bill Esterson's debates with the Department for Science, Innovation & Technology
(1 day, 16 hours ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Urgent Questions are proposed each morning by backbench MPs, and up to two may be selected each day by the Speaker. Chosen Urgent Questions are announced 30 minutes before Parliament sits each day.
Each Urgent Question requires a Government Minister to give a response on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Chris Bryant
I am afraid that I will have to write to the hon. Lady on that last question, as I am not sure precisely where we are with an impact assessment. She is absolutely right that the UK’s life sciences sector generated something like £108 billion in turnover in the financial year ending 2022—a sharp 13% increase on the previous year. We want to build on that. The sector has seen year-on-year growth since the financial year ending 2015, and turnover is now 40% higher than in the financial year ending 2022. We are keen to publish, as part of our industrial strategy, our precise plans for the financial services sector. We said that will be in the spring—it certainly still felt like winter in the Rhondda at the weekend, so I am afraid she will have to wait until spring has sprung.
Bill Esterson (Sefton Central) (Lab)
AstraZeneca is a key partner in the Liverpool city region’s life sciences innovation zone, as is Maghull health park in my constituency, with its research and development plans. Will my hon. Friend confirm that the Government will engage with partners in the city region, including the University of Liverpool, the metro mayor Steve Rotheram, council leaders and the region’s MPs, to try to recover ground on this deal, which will add to the success we have already seen with AstraZeneca in the city region and across the country?
Chris Bryant
Regional mayors have an important role to play in helping bring investment into key areas. I am happy to ensure that the meetings that my hon. Friend has asked for take place. This has to be a joint venture between everyone. I want to underline that it is not the case that AstraZeneca is leaving the United Kingdom, or that it does not have confidence in the United Kingdom, because it clearly does—it invests more than £2.5 billion every year into the UK economy. It is a key partner of the UK and will continue to be so.